Protalix BioTherapeutics (PLX) Non-Current Deffered Revenue (2010 - 2022)

Protalix BioTherapeutics has reported Non-Current Deffered Revenue for 13 years, with the latest figure at $5.9 million in Q2 2022.

• For the quarter ending Q2 2022, Non-Current Deffered Revenue rose 364.54% year-over-year to $5.9 million; the trailing twelve-month figure through Jun 2022 stood at $5.9 million (up 364.54% YoY), and the FY2021 full-year result was $11.8 million, up 587.06% from the prior year.
• Non-Current Deffered Revenue for Q2 2022 stood at $5.9 million, roughly flat from $5.9 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $34.9 million in Q2 2019, with the low at $858000.0 in Q1 2021.
• Average Non-Current Deffered Revenue over 5 years is $15.0 million, with a median of $9.5 million recorded in 2020.
• Year-over-year, Non-Current Deffered Revenue sank 94.64% in 2020 and jumped 587.06% in 2021.
• Tracing PLX's Non-Current Deffered Revenue over 5 years: stood at $33.0 million in 2018, then plunged by 48.59% to $17.0 million in 2019, then sank by 89.89% to $1.7 million in 2020, then jumped by 587.06% to $11.8 million in 2021, then slumped by 50.0% to $5.9 million in 2022.
• The last three Non-Current Deffered Revenue figures came in at $5.9 million (Q2 2022), $5.9 million (Q1 2022), and $11.8 million (Q4 2021), per Business Quant data.

Peer Comparison